Johnson & Johnson MedTech’s strategic co-promotion agreement with Pacira BioSciences marks a pivotal step in expanding early intervention options for knee osteoarthritis (OA), one of the most prevalent and disabling musculoskeletal conditions in the U.S. Through the integration of ZILRETTA®—a long-acting, extended-release corticosteroid injection for knee OA pain—into its Early Intervention portfolio, Johnson & Johnson aims to offer healthcare professionals a powerful, non-surgical tool for managing OA symptoms at earlier stages. This partnership underscores a shared commitment to reshaping the osteoarthritis treatment landscape with clinically validated, patient-centric solutions.

The burden of knee OA continues to rise as patients struggle with persistent pain and reduced mobility, despite available therapies. Many individuals often delay treatment until surgical intervention becomes necessary, underscoring a significant unmet need for longer-lasting, non-opioid therapies earlier in the disease course. ZILRETTA®’s extended duration of action offers a compelling option for improving quality of life and delaying the progression to more invasive procedures. By jointly investing in provider education and awareness efforts, both companies aim to empower clinicians to better address OA-related pain and enable timely, personalized care planning.

Looking ahead, the collaboration has the potential to drive innovation in how OA is managed across diverse care settings, from primary care to orthopaedic specialists. This initiative not only strengthens Johnson & Johnson MedTech’s commitment to delivering integrated, data-informed care across the musculoskeletal spectrum but also signals a broader industry shift toward proactive, value-based interventions. With a focus on non-opioid alternatives and earlier engagement, the partnership paves the way for improved long-term outcomes for millions of patients living with knee OA.